Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

Moderna (NASDAQ:MRNA), on Monday, reported positive results from a late-stage study comparing its influenza vaccine candidate ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Newborns are at risk for serious complications from influenza infections but are not eligible for vaccination until they are ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

The Trump administration recently canceled $766 million in contracts with Moderna to develop and produce an mRNA vaccine against pandemic influenza viruses, including H5N1 avian flu. This is a tragic ...

Moderna in May voluntarily withdrew an application seeking approval of its combination shot targeting Covid-19 and influenza, saying it had plans to resubmit it with efficacy data from the phase three ...

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

CDC advisory committee recommends thimerosal-free influenza vaccines for all adults and children, despite claims that the ...

New research uses bird droppings to track avian flu in remote regions, revealing hidden hotspots and potential for early ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...